{"product_id":"progress-in-drug-research-9783034895446","title":"Progress in Drug Research","description":"\u003cp\u003e • Author(s): Q. May Wang\u003cbr\u003e • Publisher: Springer\u003cbr\u003e • Publisher Imprint: Birkhauser\u003cbr\u003e • BISAC: General\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cp\u003eHepatitis C virus (HCV) was first identified in 1989 as the etiologic agent of non-A, non-B hepatitis [1] and is currently recognized as the leading cause of chronic liver disease worldwide. In contrast to hepatitis B virus infection, in which only about 5% of adult infections become chronic, more than 80% of HCV-infected patients develop chronic hepatitis. Moreover, 20-50% of those persistently infected with HCV will develop liver cirrhosis and hepatocellu- lar carcinoma (HCC) [2]. It is estimated that there are 10,000 deaths in the USA per year due to chronic liver failure or HCC [3]. In addition, HCV dis- 25-50% of all liver transplants in US centers, and the ease is responsible for recurrence of HCV infection following liver transplantation is universal [4]. Typically, HCV disease emerges after a 10-20 year period during which symp- toms, if they exist at all, are mild and non-specific. Although the prevalence varies greatly among different countries, it has been estimated that up to 170 million people (3% of the world's population), are infected with HCV [5]. A recent study in the USA found that 65% of all HCV-infected persons are 30 to 49 years old [6].\u003c\/p\u003e","brand":"Springer","offers":[{"title":"Paperback","offer_id":45283827810455,"sku":"9783034895446","price":3672.0,"currency_code":"INR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0666\/3471\/1191\/files\/9783034895446.webp?v=1769306022","url":"https:\/\/atlanticbooks.com\/products\/progress-in-drug-research-9783034895446","provider":"Atlantic Books","version":"1.0","type":"link"}